CURE:NYE-Direxion Daily Healthcare Bull 3X Shares (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 136.05

Change

0.00 (0.00)%

Market Cap

USD 0.20B

Volume

9.65K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index includes domestic companies from the healthcare sector, which includes: pharmaceuticals; health care equipment and supplies; health care providers and services; biotechnology; life sciences tools and services; and etc. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-21 )

ETFs Containing CURE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.72% 71% C- 92% A
Dividend Return 0.62% 43% F 13% F
Total Return 34.34% 71% C- 92% A
Trailing 12 Months  
Capital Gain 48.36% 47% F 90% A-
Dividend Return 1.31% 44% F 18% F
Total Return 49.67% 47% F 90% A-
Trailing 5 Years  
Capital Gain 155.25% 85% B 91% A-
Dividend Return 6.01% 82% B 18% F
Total Return 161.26% 83% B 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 21.48% 52% F 84% B
Dividend Return 22.07% 51% F 83% B
Total Return 0.59% 54% F 14% F
Risk Return Profile  
Volatility (Standard Deviation) 40.35% 84% B 23% F
Risk Adjusted Return 54.69% 87% B+ 72% C
Market Capitalization 0.20B 61% D- 36% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike